|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
December 01, 2005Schering shares fall on FDA Campath alert
Campath is approved to treat a type of blood cancer, but in a study on multiple sclerosis, three patients developed a severe blood disorder and one of them died, the FDA said.
The company initially reported the serious side effect in September and put the trial on hold. "This is the official posting on the FDA website that pertains exactly to the announcement we made in September. We are still in discussions with the FDA," said a Schering spokesman. Analysts said the FDA warning was anticipated, but the focus would now be on the future of the drug to treat multiple sclerosis.MORE- Boston.com |